Ocular Manifestations of Behçet’s Disease by Sahli, Esra & Gurbuz-Koz, Ozlem
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Ocular Manifestations of Behçet’s Disease
Esra Sahli and Ozlem Gurbuz-Koz
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69049
Abstract
Behçet’s disease (BD) is a multisystemic autoimmune inflammatory disorder character-
ized by oral aphthous lesions, genital ulcerations, iridocyclitis with hypopyon, and skin 
lesions. While ocular manifestations occur in nearly 50% of the patients with Behçet’s dis-
ease, ocular involvement is the initial manifestation in only less than 20% of the patients. 
Ocular Behçet’s disease clinically presents iridocyclitis with or without hypopyon, vitri-
tis, retinitis, occlusive retinal vasculitis, and cystoid macular edema. However, anterior 
uveitis is usually the only initial ocular manifestation; the most common form is panuve-
itis. The usual course of the disease is characterized by recurrent inflammatory periods. 
Recurrent inflammatory attacks may result in irreversible damage and significant visual 
loss. Early and effective treatment is required to prevent ocular morbidity. Recent devel-
opments in the treatment of ocular Behçet’s disease like biological agents are promising 
with a rapid effect and high remission rates.
Keywords: behçet’s disease, iridocyclitis, retinal vasculitis, retinitis, immunosuppressants, 
biological agents
1. Introduction
Behçet’s disease (BD) is a multisystemic autoimmune inflammatory disorder character-
ized by oral aphthous lesions, genital ulcerations, iridocyclitis with hypopyon, and skin 
lesions. It often involves the central nervous system, cardiovascular system, gastrointestinal 
system, and joints as well. An enhanced or dysregulated immune response triggered by 
environmental factors in immunogenetically susceptible individuals plays a major role in 
etiopathogenesis of the disease [1].
The prevalence of BD is higher in Eastern Mediterranean and Eastern Asia countries than in 
Northern European countries and the USA. The highest disease incidence has been reported 
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in Turkey as 20–421 per 100,000 people [2]. The prevalence rate in Japan is reported as 1/10,000 
[3]. Studies from Iran, Greece, and the USA indicate 16–100 per 100,000 people, 6 per 100,000 
people, and 4 per 1,000,000 people, respectively [4–6].
BD is an obliterative and necrotizing systemic vasculitis that involves different organ systems. 
Occlusive vasculitis is a characteristic of BD that is not typically seen in other forms of uveitis. 
It affects both arteries and veins. Its histopathological appearance is characterized by non-
granulomatous inflammation with perivascular T lymphocytes and neutrophil infiltration 
and increased expression of adhesion molecules. Local expression of proinflammatory cyto-
kines including tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β), and interleu-
kin-8 (IL-8); increased circulating immune complexes; endothelial dysfunction; and abnormal 
coagulation system play role in the pathogenesis of BD-associated vasculitis [7].
Diagnosing BD can be challenging since there are no specific laboratory tests or pathogno-
monic findings. The diagnosis relies mainly on clinical findings. Positive skin pathergy test and 
positive of HLA-B51 values can help verify the diagnosis, but these are not used exclusively 
for BD diagnosis. The most commonly used diagnostic criterion is defined by the International 
Study Group for BD. Recurrent oral ulcer that occurs at least three times a year, is mandatory 
for the diagnosis. In addition, two of the four major symptoms, including eye lesion, recurrent 
genital ulcers, skin lesions, and a positive pathergy test, are sufficient for the diagnosis of BD 
[8]. According to Behçet’s Disease Research Committee of Japan, there are four major and five 
minor criteria. The major criteria include recurrent aphthous ulcers, skin findings (similar of 
those erythema nodosum or acne and a pathergy test), genital ulcers, and ocular involvement. 
The minor criteria include arthritis, intestinal ulcers, epididymitis, vascular disease, and neu-
ropsychiatric involvement. This diagnostic system requires only one major symptom in addi-
tion to typical ocular symptoms for the diagnosis of ocular BD [9, 10].
2. Ocular involvements of Behçet’s disease
BD has wide range of clinical manifestations. While ocular manifestations occur in nearly 
50% of the patients with BD (50–70% of affected men and 20–30% of affected women), ocular 
involvement is the initial manifestation in less than 20% of the patients [11]. BD has been 
reported as the most common diagnosis (32.2%) among patients with uveitis in Turkey and 
the third most common cause of noninfectious uveitis, following sarcoidosis and Vogt-
Koyanagi-Harada disease, in Japan [12, 13].
Ocular findings generally occur within the first 2–4 years of the disease. In 80% of the patients, 
the manifestations are bilateral [14]. According to a study with a large patient group, the ratio 
of bilaterality was found 80% among men and 64% among women in the beginning of the 
disease. However, at the end of a 20-year follow-up, the ratio increased to 87% among men 
and 71% among women [15].
The gender seems to affect the clinical manifestations and prognosis. The disease usually has 
a more severe course in men with a younger age of onset. Isolated anterior uveitis has a higher 
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frequency in females than in males. Males have greater visual morbidity because of the higher 
incidence of vitritis, retinitis, retinal vasculitis (RV), and retinal hemorrhages than females. 
The course of BD may also vary due to geographical ethnic factors and individual character-
istics [14]. Although several familial cases and a pair of monozygotic twins correspondent for 
BD have been reported, no consistent inheritance pattern has been confirmed [16].
The most common form of BD is panuveitis. The usual course of the disease is characterized 
by recurrent inflammatory periods. Early recognition of ocular involvement is important, 
as uveitis management differs from extraocular involvements with high ocular morbidity. 
Despite modern treatment modalities, the disease still carries poor visual prognosis.
The ocular symptoms are usually first manifested during the third or fourth decade of life. 
The primary manifestation can be unilateral in 50–87% of patients and occurs usually as an 
anterior uveitis. Later in nearly two-thirds of the cases, it changes to bilateral panuveitis with 
a chronic relapsing course. Panuveitis is seen significantly more often in men than in women 
[3, 16, 17].
The diagnosis of ocular BD is done based on clinical findings obtained from slit-lamp biomi-
croscopy and ophthalmoscopy. In addition, fluorescein angiography (FA) and indocyanine 
green angiography (ICGA) examinations are seen to be helpful in the diagnosis [17].
Ocular BD clinically presents iridocyclitis with or without hypopyon, vitritis, retinitis, occlu-
sive RV, and cystoid macular edema (CME). Band keratopathy, glaucoma, vitreoretinal hem-
orrhage, posterior vitreous detachment, macular degeneration, epiretinal membrane, vein 
occlusion, and phthisis of the eye may also be observed as complications of ocular BD [18].
During acute inflammation, diffuse infiltration of neutrophils and lymphocytes in the iris, 
ciliary body, and choroid is seen. After recurrences, increased collagen can lead to iris atrophy, 
posterior synechiae, cyclitic membrane formation, and the thickening of the choroid. In the 
retina, infiltration of leukocytes and plasma cells in and around blood vessels and into retinal 
tissue appears, histopathologically. Veins are more affected than arteries. During the inflam-
mation, retinal vascular endothelial cells become swollen; neutrophil migration and throm-
bus formation are also seen. In more advance cases, fibrosis of blood vessels and complete 
vascular obliteration may be present. Rods and cones get destroyed. Fibrosis of the inner 
nuclear layer appears; however, the destruction of retinal pigment epithelium is minimal. 
The optic nerve vessels can be affected and can result in optic neuritis, ischemia, and finally 
optic atrophy [16].
In addition, recurrences are very common, and the recurrent attacks of ocular inflammation 
may result in severe ocular damage. BD may produce permanent vision loss in up to 20% 
of affected individuals. The poor long-term visual outcome is usually related to glaucoma, 
cataract, and RV [15].
Uveitis in BD may involve the anterior and/or the posterior segment of the eye. The location 
of the inflammation is important both therapeutically and prognostically. If the lesions affect 
the posterior segment, vision loss is usually permanent and significant. The most common 
presentation of BD is bilateral non-granulomatous panuveitis with RV.
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3. Anterior segment involvement
Anterior uveitis is usually the only initial ocular manifestation in patients with BD, and it can 
occur as an isolated finding in about 10% of the patients. This presentation is more common in 
females. Anterior uveitis, also known as iridocyclitis, is limited to the iris and the vitreous. The 
inflammatory response in the anterior chamber is of non-granulomatous nature. Although 
ocular BD is characterized by explosive acute hypopyon uveitis, a more common presentation 
is iridocyclitis without hypopyon, which is seen in two-thirds of the cases [17, 19].
Patients’ complaints are often redness, pain in the globe, photophobia, tearing, and blurred 
vision. Slit-lamp biomicroscopic examination reveals conjunctival injection, perilimbal flush, 
cells and flare in the anterior chamber, keratic precipitates, and hypopyon. Disruption of the 
blood-aqueous barrier results in aqueous flare and cells, which are the two inflammatory 
parameters of anterior chamber inflammation. Cells in the aqueous humor can be detected as 
particles identified by backscattering light from the incoming beam with slit-lamp biomicros-
copy. Grading systems have been developed to standardize quantification of cells and flare in 
the anterior chamber, based on slit-lamp examination. Increased protein content of the aque-
ous humor produces flare. It can be measured by laser flare photometry, which is an objective 
quantitative method. Yalcindag et al. reported that flare levels in the aqueous humor were cor-
related with fluorescein leakage on FA and suggested that higher flare values were associated 
with poor vision [20]. Keratic precipitate is an inflammatory cellular deposit seen usually on 
the lower part of the corneal endothelium. These precipitates are composed of the aggrega-
tion of polymorphonuclear cells and lymphocytes. They are fine, irregular, and almost always 
nonpigmented. Hypopyon is formed by the accumulation of cells and fibrin in the lower part 
of the anterior chamber of the eye. It is seen as a whitish or grayish fluid (Figure 1). Hypopyon 
includes mostly polymorphonuclear cells. Hypopyon typically freely moves and slowly shifts 
with gravity according to head position within minutes as opposed to the sticky hypopyon 
of HLA-B27-associated uveitis. The presence of hypopyon without ciliary injection is called 
Figure 1. Hypopyon in a patient with Behçet’s disease.
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“cold hypopyon.” A small layer of leucocytes can be observed in the anterior chamber angle 
by gonioscopy and is called angle hypopyon. The eye can be seen white despite inflammatory 
reaction in the anterior chamber. The hypopyon can be overlooked during the eye examination 
because this finding is transient. At the same time, hypopyon nowadays is less commonly seen 
because of earlier and more aggressive treatments. In the convalescent period of uveitis with 
hypopyon, slightly thickened pigment particles presenting as multiple dark brown spots can 
be seen in the inferior angle [17, 21].
The anterior uveitis appears very rapidly; its nature is explosive. It may get resolved spon-
taneously within 2–3 weeks even if it is not treated. Almost all nonpermanent inflammatory 
findings may disappear after each attack. Recurrent inflammatory attacks can result in struc-
tural changes of the anterior segment of the eye including posterior synechiae, iris atrophy, 
and peripheral anterior synechiae. Posterior synechiae are the adhesion between the poste-
rior iris and the anterior lens surface. Pigment epithelial cells can be seen on the lens surface 
when the pupil is dilated (Figure 2). Mydriatic agents and topical corticosteroids are useful 
in breaking and preventing the formation of posterior synechiae. Posterior synechiae may 
be segmental or annular. Seclusio pupillae, 360° adhesions of pupillary margin to anterior 
capsule of the lens, and occlusio pupillae, the presence of a fibrovascular membrane across 
the pupil, may also be seen (Figure 3). Peripheral anterior synechiae, adhesion between the 
anterior iris and cornea, may be seen in result of the dense inflammation. Peripheral anterior 
synechiae and iris bombe formation associated with seclusion of pupilla may cause secondary 
glaucoma. Neovascularization of the iris may be seen secondary to occlusive RV.
The other anterior segment changes include episcleritis, scleritis, conjunctivitis, conjuncti-
val ulcerations, and subconjunctival hemorrhages, keratitis, and rarely extraocular muscle 
paralysis.
Figure 2. Pigment epithelial cells on the lens surface when pupil is dilated in a patient with Behçet’s disease.
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4. Posterior segment involvement
The most common posterior segment findings are vitritis and RV. They are found in nearly 
90% of Behçet patients with uveitis. However, an isolated vitritis, white cell infiltration of 
the vitreous body, is not a characteristic of BD. Increased vascular permeability of the retina, 
choroid, and ciliary body vessels results in cells in the vitreous and vitreous haze. White cell 
infiltration in the vitreous ranges from variable number of cells suspended in the vitreous 
fibrils to a dense plasmoid reaction in the acute phase. Vitreous haze is usually a proteinous 
material. It is important to follow up because it demonstrates the posterior segment activa-
tion. Even though the presence of vitreous cells is considered as the evidence of activation, 
they may also be seen as the persistent opacities in the vitreous cavity. They can be displaced 
by movements of the head easily and can be evaluated with slit-lamp biomicroscopy. Vitritis 
may last in a chronic smoldering course. In most cases, posterior vitreous detachment occurs 
at an early stage of ocular disease (92%) [22].
The essential manifestation of the posterior segment in patients with ocular BD is an occlu-
sive and necrotizing RV. RV is defined as a disruption in the blood-retinal barrier and results 
in retinal vascular leakage on FA and perivascular infiltrates on dilated fundus examination 
in addition to the presence of other signs of intraocular inflammation such as cell infiltra-
tion into the vitreous, anterior chamber, retina, or choroid [23]. RV occurs as recurrent vaso-
occlusive episodes that lasts for weeks. Active periods are then followed by periods of relative 
quiescence.
In most patients, RV mainly affects the retinal veins, which is pathognomonic for BD. In addi-
tion to this, BD is the only systemic vasculitis affecting small- and medium-sized arteries and 
also veins. Venous and capillary dilatation with engorgement may also be seen (Figure 4) [21].
Retinal vasculitis can be concluded as a finding such as an intraretinal hemorrhage or cotton wool 
exudate. Intraretinal hemorrhage indicates an abnormality of retinal vessel wall. Cotton wool 
Figure 3. Posterior synechiae formation secondary to anterior uveitis in a patient with Behçet’s disease.
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exudates indicate local retinal ischemia caused by occlusive vasculitis. In BD with RV, patchy 
perivascular sheathing and whitish yellow exudates surrounding retinal hemorrhages are often 
observed. Severe RV can result in ischemic changes due to vascular occlusion. Choroidal vascular 
involvement also occurs, and choroidal infarcts can also be seen [14, 16, 24].
Based on necrotizing obliterative vasculitis, neovascularization of the optic disc and periph-
eral retina can cause retinal detachment with or without vitreous hemorrhage. The process 
could be summarized as follows: vascular occlusion causes retinal hypoxia, which stimulates 
the neovascularization of the optic disc and elsewhere. Both of them can rupture and cause 
vitreous hemorrhage. Vitreous hemorrhage may organize with transvitreal membrane for-
mation, which may exert traction on the retina. This traction may lead to rhegmatogenous or 
combined tractional-rhegmatogenous retinal detachment [1, 15].
Retinitis is the next most common posterior segment manifestation. Retinitis is evidenced by 
soft infiltrates. These soft exudates resolve spontaneously in a few weeks, but diffuse vitreous 
opacity may stay for a few months [1].
Inflammatory cell infiltrations that affect the superficial and deep layers of the retina and 
hemorrhages coexisting with infiltration appear in occasional cases. In the acute disease tran-
sient, superficial white infiltrates that heal without scarring may be observed. Exudative reti-
nal detachment may also appear after acute retinitis. Retinal atrophy can occur following the 
resolution of retinal exudates and hemorrhage [1].
Retinal edema is present in 20–75% of cases especially in the macula. Cystoid or diffuse macu-
lar edema caused by vascular leakage is one of the most important findings [15]. Optical 
coherence tomography (OCT) imaging reveals retinal thickening and is useful for follow-up. 
Thrombosis of the central retinal vein or its branches may be seen, but they are the less com-
mon findings. Occlusion of the central retinal artery is extremely rare. Bilateral retinal vein 
thromboses and bilateral posterior ischemic optic neuropathy have been reported [25, 26].
Figure 4. Fundus photograph of a patient with Behçet’s disease showing diffuse retinal vasculitis.
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The optic nerve is affected in at least one-fourth of patients with BD. This condition may either 
present as an isolated papillitis or as a finding of sagittal sinus thrombosis due to neurologi-
cal involvement of BD. Papillitis with optic disc hyperemia and blurring of the margins is the 
most common involvement of the optic nerve. Optic disc edema may occur as a result of the 
microvasculitis of the arterioles supplying the optic disc. While it is not seen very often, it can 
lead to progressive optic atrophy [15].
End-stage disease is characterized by optic atrophy, gliosis and sheathing, and attenuation of 
retinal vessels and ghost vessels. Destructive and recurrent attacks of uveitis especially with 
posterior segment involvement may result in permanent damage in the sensory retina, causing 
irreversible loss of vision.
5. Complementary imaging modalities and laboratory tests
Fluorescein angiography is essential and gold standard in evaluating the activity and the 
extent of the vasculitis in Behçet patients. FA demonstrates fluorescein staining on the vessel 
wall and/or fluorescein leakage from the vessel, which shows increased vascular permeability 
caused by the breakdown of the inner blood-retinal barrier, in RV.
If the posterior segment of the eye is involved, FA may reveal macular hyperfluorescence or 
perivascular staining with dye leakage from the dilated retinal capillaries even before retinal 
perivasculitis can be detected ophthalmoscopically [17]. FA provides a significant contribu-
tion in detecting vascular leakage, demonstrating the presence of macular edema, capillary 
non-perfusion, occlusion of the retinal vessels, collateral formation, and neovascularization in 
BD (Figure 5). Atmaca reported that FA revealed fluorescein leakage from retinal vessels in 
6.3% of Behçet patients who had no vision loss or no abnormal findings on fundus examina-
tion, in 1989 [27].
Figure 5. Fluorescein angiography of a patient with Behçet’s disease revealing diffuse fluorescein leakage from retinal 
vessels and cystoid macular edema.
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“Fern-like fluorescein leakage” due to inflammation at retinal capillaries is clearly demon-
strated on the mid-phase FA, and it is a characteristic finding and the most frequent fluorescein 
angiographic appearance of BD (Figure 6). Fluorescein leakage from retinal capillaries is seen 
not only during the inflammatory period but also during the apparently quiescent periods 
between attacks. It may be the only sign of persistent inflammation in the posterior segment 
during clinically inactive periods. These findings have a high diagnostic value in BD [13, 19].
Determination of FA findings is important to evaluate the severity of the disease and the 
response to the treatment. All classifications were based on the late phase of angiogram. FA 
findings are classified based on the extent of the vascular leakage as focal and diffuse, accord-
ing to macular involvement as incomplete perifoveal hyperfluorescence, mild 360° hyper-
fluorescence, moderate 360° hyperfluorescence (nearly 1 disc diameter across), and severe 
360° hyperfluorescence (nearly 1.5 disc diameter across). Corresponding to optic disc hyper-
fluorescence in the late angiographic phases, the findings can be categorized as none (normal 
exiting of fluorescein and normal staining of the sclera rim), partial, diffuse without blurring 
of the disc margin, and diffuse with blurring of the disc margin [28].
Kim et al. investigated whether there is correlation between FA findings and visual acuity 
(VA) in Behçet patients with RV. Retinal vascular leakage, optic disc hyperfluorescence, and 
macular leakage were seen to be associated with a decreased VA [29].
Visualization of the peripheral retina by an ultrawide-field retinal imaging system may be 
useful to diagnose and monitor RV in Behçet patients and in the treatment of the disease. 
Conventional fundus cameras can capture only 30–60° of the fundus at a time and cannot 
image the entire retina simultaneously. The ultrawide-field imaging system provides 200° of 
photographic and angiographic views of the ocular fundus [30]. Improved visualization of 
the peripheral retina by ultrawide-field imaging has demonstrated that peripheral RV could 
be detected in 85% of eyes that did not have ophthalmoscopic evidence [31].
Figure 6. “Fern-like” fluorescein leakage from peripheral retinal vessels on fluorescein angiography.
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Choroidal and retinal pigment epithelial changes are rarely seen in ocular BD. The BD patients 
with choroidal abnormalities could only be evaluated with ICGA and not with fundus examina-
tion or FA [32]. In these cases, ICGA may have an advantage over FA in showing lesions, cho-
roidal vessel leakage, irregular filling of the choriocapillaris, and choroidal filling defects. ICGA 
was demonstrated with no clinically useful information on disease activity and monitoring the 
disease. ICGA is used to evaluate choroidal involvement in inflammation of the posterior seg-
ment [32, 33]. Since the choroidal infarcts are probably more common than they are usually esti-
mated, simultaneous ICGA and FA would be useful for examining choroidal involvement in BD.
OCT provides both high-resolution cross-sectional imaging of the retina and quantitative 
measurement of the retinal thickness. For the detection and follow-up of macular edema in 
BD, OCT and FA are both necessary and complementary. The integrity of junctions between 
inner and outer segments of the photoreceptors (ISOS line) and the cone outer segment tip 
line (interdigitation zone) are correlated with visual function and prognosis in patients with 
uveitic macular edema, and these zones are best evaluated by OCT [34, 35].
Transient retinal infiltrates, which are commonly seen during exacerbations of Behçet’s uve-
itis, are indicated as focal retinal thickening; increased hyper-reflectivity with blurring, espe-
cially of inner retinal layers; and optical shadowing by spectral-domain OCT. In Behçet’s 
uveitis, retinal infiltrates rapidly resolve without any apparent retinochoroidal scarring. 
However, inner retinal atrophy is seen in the spectral-domain OCT sections [34].
Recently, the assessment of choroidal thickness has been possible by the enhanced depth 
imaging (EDI) mode of spectral-domain OCT in patients with Behçet’s uveitis. Ishikawa et al. 
and Kim et al. reported that subfoveal choroidal thickness was significantly higher during an 
acute attack of Behçet’s uveitis than in remission. Their choroid was found thicker than that 
of healthy control subjects not only during an attack of Behçet’s uveitis but also during remis-
sion of the disease [36, 37].
Elevated erythrocyte sedimentation rate, positive C-reactive protein, and increased periph-
eral blood leukocytes, which are nonspecific factors indicative of immune system activation, 
may be abnormal during the acute phase of BD. The other acute phase reactants such as pro-
perdin factor-b and alpha-1-acid glycoprotein may also be elevated [16].
6. Management of ocular Behçet’s disease
Behçet’s uveitis has a remitting and relapsing course, and recurrent inflammatory attacks 
may result in irreversible damage and significant visual loss. It is one of the most difficult 
forms of uveitis to treat. The aim of the treatment should be to obtain a rapid resolution of 
inflammation, to prevent or at least reduce the frequency of attacks, and to avoid complica-
tions. There is no standard treatment protocol. The choice of therapy is based on the severity 
of the disease. Combination therapy is required in most of the patients. Early and aggressive 
treatment should be administered whenever following features are present: male sex, young 
age, characteristic geographical origin, complete BD (the presence of oral and genital ulcer, 
ocular and skin findings simultaneously or at different times), posterior segment and bilateral 
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involvement, and central nervous system or vascular involvement [4]. The therapy in BD 
should be highly effective for preferably manifestations, should effect rapidly, have fewer 
side effects, and should be as cheap as possible.
6.1. Corticosteroid therapy
Local and systemic steroids especially during attacks are used very commonly. Corticosteroids 
help suppress the ocular inflammation rapidly but have potential side effects including glau-
coma and cataract.
In the treatment of anterior uveitis, topical corticosteroid drops (prednisolone acetate, dexa-
methasone phosphate) should be used to suppress the inflammatory response. It can be discon-
tinued upon vanishing the anterior chamber cells after nearly 6–8 weeks of application. Relapses 
and severe exacerbations may develop when dose is lowered. Therefore, stepwise tapering the 
corticosteroid dose is needed. Corticosteroid-induced ocular hypertension and cataract devel-
opment are possible risks of the treatment. Topical nonsteroidal anti-inflammatory drugs such 
as indomethacin, diclofenac, and flurbiprophen could be added to topical corticosteroids to 
potentiate the corticosteroid activity. Topical mydriatic and cycloplegic agents should be added 
twice or three times a day (tropicamide 1%, cyclopentolate 1%, and phenylephrine 2.5 and 10%) 
in order to relieve photophobia, pain, and discomfort and prevent synechiae formation [38, 39].
Patients with severe anterior uveitis unresponsive to topical treatment may benefit from sub-
tenon or subconjunctival injections of depot corticosteroids such as triamcinolone acetonide or 
methylprednisolone acetate every 2–4 weeks for 4–5 times. Depot steroids ensure long-lasting 
suppression of the inflammation. However side effects such as conjunctival hemorrhage or 
scarring, encapsulated cyst, ptosis, and accidental eye perforation may occur. Subconjunctival 
corticosteroid injection can be administered for treating hypopyon and severe anterior seg-
ment inflammation with fibrin clotting [38, 39].
When topical and local administration is not effective, a short course of oral corticosteroids 
(prednisolone, 1–2 mg/kg/day), colchicine, or methotrexate may be used in addition. High-
dose systemic corticosteroids are used for the treatment of severe posterior uveitis and panu-
veitis attacks. Intravenous pulse methylprednisolone (1 g/day) is usually administered for 3 
consecutive days to obtain a rapid anti-inflammatory effect. Then oral prednisone (1–1.5 mg/
kg/day) is given in a single morning dose and slowly tapered to a maintenance dose of 7.5 mg/
day or less after complete resolution of active inflammation. If exacerbation is encountered 
under the dose of 0.5 mg/kg/day, steroid may be stopped, and another immunosuppressant 
agent can be started. Long-term treatment with systemic corticosteroid should not be pre-
ferred. Elevation of intraocular pressure (IOP), cataract, cushingoid state, GI ulcers, osteopo-
rosis, diabetes mellitus, and exacerbations of infections are some of the important side effects 
of systemic corticosteroid treatment [17, 38, 39].
6.2. Immunomodulatory therapy
Behçet patients with acute and severe posterior segment involvement may benefit from sys-
temic corticosteroid treatment in early stages. The prolonged use of systemic  corticosteroids 
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must be avoided, because severe rebound attacks can occur during tapering the dose. Despite 
the fact that corticosteroids alone have failed to prevent vision loss in patients with BD, their 
immediate anti-inflammatory effect is useful while waiting for the immunosuppressant agents 
to effect fully. The corticosteroids should be tapered rapidly within weeks and immunosup-
pressant agents should start. A single long-term immunosuppressant agent is initially admin-
istered as monotherapy for at least 6–12 months. Conventional immunosuppressive agents 
that have been used for the treatment of BD uveitis with posterior segment involvement 
include antimetabolites (methotrexate, azathioprine, mycophenolate), calcineurin inhibitors 
(cyclosporine A, tacrolimus, sirolimus), and alkylating agents (chlorambucil, cyclophospha-
mide). If the disease does not respond to these drugs, the dose is increased or the drug is 
changed to another one. The combination of two cytotoxic immunosuppressants (methotrex-
ate, azathioprine, chlorambucil, and cyclophosphamide) can be tried in patients with severe 
RV [17, 38].
In selected patients, low-dose corticosteroids, at the dose of equal or less than 10 mg/day, may 
be required chronically in combination with immunosuppressants for controlling uveitis. This 
combination is beneficial for reducing the adverse effects of either immunosuppressants or 
corticosteroids.
6.2.1. Azathioprine
Azathioprine is an antimetabolite drug that interferes with purine incorporation into DNA 
and affects rapidly proliferating cells such as activated lymphocytes [16]. Azathioprine can 
be administered alone or in combination with corticosteroids and other immunosuppressives 
at the dose of 2–2.5 mg/kg/day. Important side effects of Azathioprine are fever, reversible 
bone marrow suppression, hepatotoxicity, hyperuricemia, pancreatitis, and increasing risk 
of malignancies. Complete blood count (CBC) and liver function tests (LFT) should be per-
formed every 2 weeks for the first month and then once every 3 months [17]. The patients who 
initially received azathioprine treatment especially within 2 years after disease onset have a 
better visual prognosis and less risk of new eye disease [40].
6.2.2. Methotrexate
Methotrexate is an antimetabolite drug that prevents the activation of folic acid, necessary 
for synthesis of DNA. Methotrexate is suggested at the dose of 7.5–20 mg/week perorally. 
Gastrointestinal upset, bone marrow suppression, hepatorenal toxicity, central nervous sys-
tem toxicity, sterility, alopecia, and anorexia are potential side effects of methotrexate. CBC 
and LFT should be ordered every 2 weeks for the first month and then once a month [17].
6.2.3. Mycophenolate mofetil
Mycophenolate mofetil is an antimetabolite drug that blocks DNA synthesis by the inhibition 
of enzyme inosine monophosphate dehydrogenase. It does not inhibit the early production of 
cytokines of T-helper-cell clones (Th0 and Th2); it acts synergistically with other immunosup-
pressive agents [16]. Larkin and Lightman reported successfully treated Behçet patients by 
adding mycophenolate mofetil to their combination of steroid and cyclosporine [41].
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6.2.4. Cyclosporine A
Cyclosporine A is a noncytotoxic immunomodulatory agent, which selectively and reversibly 
inhibits T-helper-lymphocyte-mediated immune responses. It binds to and inhibits calcineu-
rin by forming cyclosporine-cyclophilin complex. Calcineurin catalyzes reactions necessary 
for early activation of T cells and production and expression of cytokines such as IL-2 [42]. 
Cyclosporine A has been shown to reduce frequency and severity of uveitis attacks and is 
administered at the dose of 3–5 mg/kg/day in two divided doses. It induces rapid suppression 
of intraocular inflammation. Cyclosporine A is safer than the cytotoxic agents in the man-
agement of posterior segment manifestations and inflammatory recurrences, and it is usu-
ally combined with systemic corticosteroids [43]. Cyclosporine A is shown to provide rapid 
improvement in VA and decrease in the frequency and severity of ocular attacks in ocular 
Behçet patients in three randomized controlled trials [44–46].
After corticosteroids are withdrawn, cyclosporine A is tapered down 10% of dose every month 
to the minimum effective dose to control the disease. But even at low doses, long-term treat-
ment is limited to the development of side effects, including hypertension, nephrotoxicity, 
arrhythmia, headache, gum hyperplasia, hirsutism, female reproductive disorder, diabetes, 
hepatotoxicity, and myelosuppression. Rebound attacks may occur following discontinuation 
or even during tapering of the dose. Cyclosporine A is demonstrated to be associated with an 
increased risk of parenchymal neuro-Behçet’s disease and is contraindicated in patients with 
neurological involvement [17, 38].
6.2.5. Tacrolimus (FK-506)
Tacrolimus suppresses CD4+ T lymphocytes similar to cyclosporine A. However, it has a 
better safety profile than cyclosporine. Favorable results in 75% of patients with refractory 
uveitis, who had been using corticosteroids, colchicine, cyclophosphamide, and cyclosporine, 
have been reported by the Japanese FK-506 Study Group on Refractory Uveitis [47]. However, 
the use of tacrolimus on the treatment of ocular BD is very limited.
6.2.6. Chlorambucil
Chlorambucil is a slow-acting alkylating agent. The usual dose of chlorambucil is 0.1 mg/
kg/day. Immunosuppressive effect of chlorambucil appears in 1–3 months of therapy [16]. 
Chlorambucil has been reported to provide even a durable remission after its discontinuation, 
but its potential serious side effects including an increasing risk of malignancy and azoosper-
mia in men have limited its use in ocular BD. It is suggested only as the last option before the 
biological agents are available [38].
6.2.7. Cyclophosphamide
Cyclophosphamide is a fast-acting alkylating agent. It can be administrated orally or intrave-
nously. The recommended dose of cyclosporine is 1–2 mg/kg/day, which may be increased to 
3–4 mg/kg/day for several weeks in selected, severe cases only. For long-term treatment, the 
dose must be adjusted according to the therapeutic response, renal function, and leukocyte 
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count. The intravenous administration is indicated in cases like patients with occlusive RV 
where a fast onset of therapeutic effect is important to preserve VA. A bolus of 15–20 mg/kg 
is given every 3–4 weeks [48].
It has been reported that cyclophosphamide showed favorable results in controlling uveitis, 
preventing ocular attacks, and maintaining a good VA for a long time in patients with BD. 
There are also reports demonstrating that cyclophosphamide therapy is superior to steroids 
and cyclosporine in the management of ocular BD [43, 48, 49].
6.3. Biological agents
Severe RV secondary to BD is often treated with monoclonal antibody against TNF-α or 
IFN-α in some centers. Some authors prefer to use biological agents alone because of less risk 
of side effects and infection and less cost, but usually the authors add anti-TNF therapy to 
antimetabolites and then consider discontinuation of the antimetabolite therapy gradually in 
a period of 6–12 months, if complete control of ocular inflammation is achieved.
6.3.1. Antitumor necrosis factor agents
Several studies suggest a central pathogenic role of TNF-α in the pathogenesis of BD uveitis. 
TNF-α is produced by mononuclear cells in the peripheral blood as part of the inflammatory 
cascade in BD. Levels of TNF-α and soluble TNF receptors are elevated in serum and aqueous 
humor in patients with BD [50–52].
Currently, available anti-TNF-α agents include etanercept (a recombinant fusion protein, 
combining 2 human p75 TNF-α receptors linked to the Fc domain of human IgG1), infliximab 
(a mouse-human chimeric monoclonal IgG1 anti-TNF-α antibody), and adalimumab (a fully 
humanized monoclonal IgG1 anti-TNF-α antibody). Although it is useful in the management 
of many rheumatologic diseases, etanercept does not seem to be an effective treatment for 
ocular BD [16].
Refractory ocular involvement is the main indication for anti-TNF treatment in BD; the ben-
eficial effects of these agents have been reported in extraocular manifestations such as gastro-
intestinal, vascular, and neurological manifestations of BD as well [53, 54].
6.3.1.1. Infliximab
Infliximab (Remicade, Bausch & Lomb, Rochester, New York, USA) is a chimeric monoclonal 
antibody directed against TNF-α. It neutralizes membrane-bound TNF-α and soluble TNF-α, 
suppresses the production of TNF-α by macrophages and lymphocytes, and induces Treg cells that acquire suppressive function in the periphery. It is administered as intravenous infu-
sions, at the dose of 5 mg/kg (3–10 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks.
Infliximab is used in refractory sight-threatening cases. Regarding the safety profile, inflix-
imab therapy is well tolerated with few adverse events including opportunistic infections, 
lupus-like reactions, multiple sclerosis, dyspnea, and hypotension and increased risk of 
malignancy.
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Infliximab has been found to be efficient and well tolerated in ocular BD. Patients with two 
or more attacks of active posterior or panuveitis in a year and patients with chronic CME are 
likely to benefit biological agents. It is demonstrated that significant decrease in inflamma-
tion, improved VA, reduced ocular complications, and the number of relapses were observed 
in infliximab compared with corticosteroid and immunosuppressive therapy [55–57].
Summarizing recent reports evaluating the effect of repetitive infliximab therapy in BD, clini-
cal responses to the therapy were achieved in 90, 89, 100, and 91% of patients with resistant 
mucocutaneous, ocular, gastrointestinal, and central nervous system involvement, respec-
tively [58].
6.3.1.2. Adalimumab
Adalimumab (Humira, Abbvie Inc., North Chicago, IL, USA) is a fully recombinant human 
immunoglobulin G1 monoclonal antibody that specifically binds to membrane and soluble 
human TNF-α with high affinity and inhibits its binding to TNF receptors. Adalimumab is 
suggested to be administered at a dose of 40 mg/week, subcutaneously. In patients with sight-
threatening Behçet’s uveitis who were switched from infliximab to adalimumab, improve-
ment in VA, decreasing in recurrences, and even complete resolution of inflammation have 
been demonstrated [59–61].
6.3.1.3. Golimumab
Another TNF-α inhibitor, golimumab, is a fully human monoclonal antibody with reduced 
immunogenicity. It has an advantage of longer half-life that allows monthly subcutaneous 
injections. Few data are available evaluating the efficacy of golimumab in BD uveitis [62].
6.3.2. Interferon-alpha
Interferon-alpha (IFN-α) is a natural cytokine produced by plasmacytoid dendritic cells. 
It induces T helper type 1 cells, T cytotoxic cells, and natural killer cells and increases the 
production of anti-IL-1 receptor antagonist. Interferons can influence both innate and adap-
tive immune responses [16, 38]. It is generally administered subcutaneously with a dose 3–6 
million IU, most often three times weekly. IFN-α should not be used in pregnant patients. 
Immunosuppressive drugs should be stopped completely before the initiation of IFN-α. 
Systemic corticosteroids should be tapered to a dose of 10 mg prednisolone equivalent per 
day as soon as possible because of the antagonistic effect of corticosteroids [63, 64]. Adverse 
effects of IFN-α including flu-like reactions (90%), fever, mild leucopenia (30%), alopecia 
(10%), depression (8%), and thyroiditis are common. Gastrointestinal disturbances, increase 
of liver enzymes, transient paresthesia, and epilepsy may also be seen [64–66].
IFN-α is recommended for the treatment of severe eye involvement of BD by European 
League against Rheumatism (EULAR) in the light of several uncontrolled studies demonstrat-
ing a fast onset of action and high remission rates. The remission may persist after withdrawal 
of the agent. IFN-α has been included in the EULAR recommendation equal to TNF-α block-
ers [67]. It works fast enough to be used in the acute phase of BD with panuveitis and/or RV 
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unresponsive to at least one immunosuppressive drug. A quick response within 2–4 weeks, 
complete or partial remission of uveitis, is achieved in almost all patients with BD [64, 68–70].
IFN-α has been shown to improve VA, resolve vitritis, and control RV and CME in most cases 
with BD [66, 68–70]. A reperfusion of occluded retinal vessels and complete regression of retinal 
neovascularization has been demonstrated with IFN-α. These effects may prevent the vision 
loss because occlusive vasculopathy develops despite the use of immunosuppressants [71, 72].
It is suggested that long-term remission seems to be associated with higher doses of IFN-α, 
but not with longer treatment durations. But IFN-α treatment with high initial doses, such as 
3–6 million IU per day, may cause more side effects such as depression [64].
6.3.3. Interleukin-1 inhibition
IL-1β is a potent proinflammatory cytokine that is involved in the early response of the immune 
system in conditions of infection and tissue injury. In autoinflammatory disorders, IL-1 block-
age results in a rapid and continuous reduction of disease manifestations. Serum levels of IL-1β 
and IL-1 receptor antagonist were found to be significantly higher in Behçet patients [38, 73, 74].
The three anti-IL-1 agents that have been used in BD are IL-1 receptor antagonist anakinra, 
anti-IL-1β monoclonal antibody canakinumab, and recombinant humanized anti-IL-1β 
gevokizumab. A retrospective multicenter study reported the efficacy and safety of anakinra 
and canakinumab in BD. Anakinra and canakinumab were well tolerated with no serious 
adverse effects except injection site reactions caused by anakinra. These agents should be 
interpreted with caution because of unavailability of controlled study [75].
IL-1 inhibition is a promising target in managing BD. The pathogenic, clinical, and therapeutic 
data supporting the use of IL-1 inhibitors in BD has been reviewed very recently. Anti-IL-1 
therapy might also be a safer option than anti-TNF-α treatment because of lower risk of oppor-
tunistic infections such as tuberculosis [76, 77].
6.4. Intravitreal therapies
Intravitreal injections have advantage of avoiding systemic adverse events and disadvantages 
of decreased risk associated with intraocular administration and the absence of systemic ben-
efits in patients with extraocular manifestations. When ocular inflammation is unilateral or 
asymmetric or when systemic administration is less desirable like during pregnancy, intravit-
real injections may be preferable [39].
6.4.1. Intravitreal triamcinolone acetonide
Intravitreal triamcinolone acetonide (IVTA) has been administered in Behçet patients with CME, 
sight-threatening uveitis, or resistant posterior uveitis. Anatomical improvement and increase 
in VA have been demonstrated. Intravitreal treatment has been enabled tapering the dose of 
systemic medications. Triamcinolone acetonide is administered 4 mg (0.1 ml) intravitreally. 
Intravitreal triamcinolone is an effective, short-term therapeutic option. Repeated injections are 
usually needed. IVTA has no significant systemic side effects, but elevation of IOP and cataract 
progression is not rare. These side effects are limiting its efficacy and repeatability [78–82].
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6.4.2. Intravitreal dexamethasone implant
Intravitreal dexamethasone implant (Ozurdex, Allergan Inc., Irvine, California, USA) has 
been shown to be effective in controlling intraocular inflammation and achieving reduction 
of central macular thickness in noninfectious intermediate and posterior uveitis in several 
studies. Therefore, the number of administration required in patients with uveitis is still con-
troversial [83–85].
It was demonstrated that intravitreal dexamethasone implant has a side effect profile which 
include cataract formation with an incidence of 15% and IOP elevation with an incidence of 
23% in patients with noninfectious uveitis [83].
6.4.3. Intravitreal fluocinolone acetonide implant
A long-term slow-release intravitreal fluocinolone acetonide implant (Retisert, Bausch & 
Lomb, Rochester, New York, USA) has been used in uveitis, and its efficacy and safety have 
been assessed by multicenter randomized clinical studies. Retisert is implanted surgically; it 
is placed through a pars plana incision and sutured to the sclera. It releases 0.59 mg of fluo-
cinolone acetonide at a constant rate during 3 years [86, 87].
In a multicenter trial that compared fluocinolone acetonide implant with aggressive oral sys-
temic therapy in patients with intermediate and posterior panuveitis, no significant difference 
between groups was found in VA, but the implant was found better and faster in controlling 
inflammation [88]. Another multicenter randomized study confirmed the superiority of the 
implant to control intraocular inflammation over standard systemic treatment in resistant 
noninfectious posterior uveitis.
6.4.4. Intravitreal antitumor necrosis factor
Intravitreal infliximab in the dose of 1–1.5 mg/0.05 ml and frequency of three times at 
6-week intervals has been found to be effective and well tolerated. In the studies investigat-
ing the efficacy of intravitreal infliximab administration in patients with chronic noninfec-
tious uveitis, improvement in vision, reduction in central foveal thickness, and reduction 
in inflammation have been demonstrated. Some cases have been reported such as vitreous 
opacifications and newly onset of severe panuveitis as adverse events after intravitreal inf-
liximab. Infliximab has been suggested to be a promising agent for refractory eye disease in 
combination with other immunosuppressants. It is important to be cautious for reactivation 
of tuberculosis [89–94].
6.4.5. Intravitreal anti-VEGF agents
There are several studies that compared the use of intravitreal bevacizumab (IVB) with IVTA 
in the literature. IVTA was found superior to IVB in visual improvement and decreasing mac-
ular thickness in refractory uveitic CME [95, 96]. Conversely, Bae et al. concluded that IVB is 
a well-tolerated and effective supplementary therapy for persistent uveitic CME, especially 
in Behçet patients [97].
Ocular Manifestations of Behçet’s Disease
http://dx.doi.org/10.5772/intechopen.69049
127
7. Prognosis and complications
Despite the use of steroids, immunomodulatory and biological agents, some patients may 
have poor final VA. Twenty-five percent to fifty percent of the patients have best corrected VA 
less than 20/200 after 5 years [98]. Aqueous protein and cells in anterior chamber, posterior 
synechiae formation, hypopyon, cataract formation, vitreous cells and exudates, posterior vit-
reous detachment, and CME may cause transient decrease in VA. Optic atrophy and resistant 
uveitic glaucoma may result in permanent visual loss at end-stage disease.
Attacks of RV, retinitis, retinal neovascularization, and vitritis lead to vitreous hemorrhage 
and retinal atrophy. In advance cases, fibrotic, attenuated retinal arterioles; narrowed and 
occluded “silver wired” vessels; alterations of retinal pigment epithelium; chorioretinal scars; 
and optic atrophy may be seen.
Inflammation and treatment modalities that are used in BD may cause complications. 
Complicated cataract and secondary glaucoma are usually associated with inflammation and 
steroid use. Repeated intraocular inflammation can lead to secondary glaucoma. Both open-
angle and angle-closure glaucoma or even pupillary block may be seen. Retinal ischemia can 
cause neovascular glaucoma. Neovascular glaucoma appears in nearly 6% of patients with 
BD. Ciliary body involvement can cause a decrease in intraocular pressure, and finally phthi-
sis bulbi may occur [15].
Vitreous hemorrhages are seen frequently in Behçet patients with severe retinal involvement. 
It can lead to organization with membrane formation, causing retinal holes and subsequent 
retinal detachment. Phthisis bulbi may finally occur. If the vitreous hemorrhage does not 
resolve spontaneously, it may be treated with pars plana vitrectomy.
Epiretinal membrane, membrane-shaped fibrosis especially in the macular region, is caused 
by posterior segment inflammation. Inflammation condensed over the macula and fibrous 
band between the posterior vitreous and retina result in macular hole formation. In the 
patients with epiretinal membrane, if the vision is seriously affected, the membrane may be 
removed surgically [16].
Recent advances in ophthalmic imaging methods have allowed to a better definition of visual 
prognosis in ocular BD. Identification of the high-risk group and the use of effective biologic 
agents as first line treatment will improve the prognosis in this potentially blinding disease.
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